Diffuse Proliferative Lupus Nephritis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diffuse proliferative lupus nephritis. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
76/100
Avg vulnerability
—
Annual revenue covered

Originators in Diffuse Proliferative Lupus Nephritis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diffuse proliferative lupus nephritis. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
27
1
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
8168218 Deltasone method of use 80 2028-01-07

Related